Vogenx, Inc. (VOGX)
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Vogenx Inc.
No financial data available.
No debt & equity data available.
No splits on record
Nothing in VOGX's public trading history: no forward or reverse split has affected the share count.
No balance sheet details available.
No income statement data available.
No balance sheet data available.
No cash flow data available.